Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06752759 · ClinicalTrials.gov registry record · Phase 3
Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting
A Phase 3 study of Peripheral Nervous System Agents and Ketamine, sponsored by Theresa Jacob, PhD, MPH.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06752759: Recruiting Phase 3 study of Peripheral Nervous System Agents and Ketamine, sponsored by Theresa Jacob, PhD, MPH.
NCT06752759 is a Phase 3 study of Peripheral Nervous System Agents and Ketamine that is actively recruiting participants, run by Theresa Jacob, PhD, MPH. The registered enrollment target is 40 participants, below the 315-participant average among 3 other Peripheral Nervous System Agents trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06752759, a Phase 3 study of Peripheral Nervous System Agents and Ketamine, is actively recruiting participants, sponsored by Theresa Jacob, PhD, MPH.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double blind active placebo controlled clinical trial for individuals within an inpatient setting with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
Primary Outcome
Montgomery-Asberg Depression Rating Scale (MADRS) has a range from 0 to 60, where the lower score indicates the better health status. Change in mean total Montgomery Asberg Depression Rating Scale (MADRS) score from the baseline (pre-dose day 1 ), Day 2 and last day of assessments (Day 8 or Day 10)
Conditions Studied
Interventions
- DRUG nebulized ketamine
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-10-16 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 3 |
What NCT06752759 shows while recruiting
NCT06752759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 315-participant average among 3 other Peripheral Nervous System Agents trials with a reported enrollment target (87% lower).
The record links to 10 conditions, with Peripheral Nervous System Agents appearing as the primary indexed condition, and to 1 intervention - of which nebulized ketamine is the first listed.
NCT06752759 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06752759 about?
NCT06752759 is a clinical study titled "Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting". This is a double blind active placebo controlled clinical trial for individuals within an inpatient setting with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.
What is the current status of trial NCT06752759?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 40 participants. The study started on 2024-10-16. Estimated completion is 2026-09-30.
What conditions does trial NCT06752759 study?
This clinical trial studies the following conditions: Peripheral Nervous System Agents, Ketamine, Neurotransmitter Agents, Physiologic Effects of Drugs, Moderate Depression.
What interventions are being tested in trial NCT06752759?
The interventions under investigation include: nebulized ketamine (DRUG).
Who is sponsoring clinical trial NCT06752759?
This trial is sponsored by Theresa Jacob, PhD, MPH, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06752759 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Nervous System Agents
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
RECRUITING · Phase 3
-
Natural History of Depression, Bipolar Disorder and Suicide Risk
RECRUITING
-
Evaluation of Abdominal Wall Block With Liposomal Bupivacaine for Post-Operative Analgesia in Donor Nephrectomy
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI